Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Acquired von Willebrand syndrome associated with a smoldering multiple myeloma, successfully treated by daratumumab, lenalidomide and dexamethasone
CONCLUSION: Daratumumab, lenalidomide, and dexamethasone demonstrated as a rapid and effective treatment for a patient with severe AvWS and multiple bleeding complications.PMID:38359808 | DOI:10.1159/000536650 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Michael Iarossi Marie-Christiane Madeleine Vekemans Nicolas Weynants Cedric Hermans Source Type: research
Lenalidomide treatment of isolated central nervous system relapse in acute lymphoblastic leukemia after HSCT and CAR-T cell therapy
CONCLUSION: Lenalidomide might be a therapeutic strategy for isolated CNS relapse after HSCT and CAR-T cell therapy.PMID:38359803 | DOI:10.1159/000537719 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Qing Zhang Yi Dong Zhimin Zhai Lili Tao Qianshan Tao Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Acquired von Willebrand syndrome associated with a smoldering multiple myeloma, successfully treated by daratumumab, lenalidomide and dexamethasone
CONCLUSION: Daratumumab, lenalidomide, and dexamethasone demonstrated as a rapid and effective treatment for a patient with severe AvWS and multiple bleeding complications.PMID:38359808 | DOI:10.1159/000536650 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Michael Iarossi Marie-Christiane Madeleine Vekemans Nicolas Weynants Cedric Hermans Source Type: research
Lenalidomide treatment of isolated central nervous system relapse in acute lymphoblastic leukemia after HSCT and CAR-T cell therapy
CONCLUSION: Lenalidomide might be a therapeutic strategy for isolated CNS relapse after HSCT and CAR-T cell therapy.PMID:38359803 | DOI:10.1159/000537719 (Source: Acta Haematologica)
Source: Acta Haematologica - February 15, 2024 Category: Hematology Authors: Qing Zhang Yi Dong Zhimin Zhai Lili Tao Qianshan Tao Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.ABSTRACTPreclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients with newly diagnosed multiple myeloma. 36 patients (median age 72.5 years) were randomized to receive belamaf at three different doses (2.5/1.9/1.4 mg/kg) every 8 weeks (q8w). Dosing schedule was extended t...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Despina Fotiou Magdalini Migkou Foteini Theodorakakou Vasiliki Spiliopoulou Ioannis V Kostopoulos Rodanthi-Eleni Syrigou Evangelos Eleutherakis-Papaiakovou Stavros Source Type: research
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283058. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of 'cure' remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance/smoldering Myeloma (MGUS/SMM)). Two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several development...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Monika Engelhardt K Martin Kort üm Hartmut Goldschmidt Maximilian Merz Source Type: research
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834. Online ahead of print.ABSTRACTNot available.PMID:38356447 | DOI:10.3324/haematol.2023.284834 (Source: Haematologica)
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Xianggui Yuan Yaping Xie Nengwen Xu Hui Liu Panpan Chen Aiqi Zhao Yun Liang Wenbin Qian Source Type: research
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research
